← All stocks

Braveheart Bio, Inc.

BRVE No buying or selling

CIK 0002131524 #2086 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

$0.00

$0.00 against sales at will

By person

11 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Forbion Growth Opportunities Fund III Cooperatief U.A. entity

10% owner

—

21,826,024

$392.87M

+1,879%

AH Bio Fund IV, L.P. entity

10% owner

—

10,232,420

$184.18M

—

Jiangsu Hengrui Pharmaceuticals Co., Ltd. entity

10% owner

—

7,420,091

$133.56M

—

Murdoch Travis

CEO and President

—

2,940,670

$52.93M

+2.9%

Viehbacher Christopher

Director

—

609,519

$10.97M

+15.8%

Malek David I

Director

—

533,845

$9.61M

+0.8%

Rickey James Paul

Chief Financial Officer

—

520,927

$9.38M

+5.6%

Anderson Michele A.

Chief Development Officer

—

332,161

$5.98M

+0.3%

ORBIMED ADVISORS LLC entity

Director

—

273,333

$4.92M

—

Chimovits Erez

Director

—

273,333

$4.92M

—

Lubner David Charles

Director

—

55,555

$999.99K

—

No percentages here. Braveheart Bio, Inc. reports its share count only per share class, which the XBRL frames API does not carry.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 0

History held since 7 Aug 2026